A type of cholesterol-related particle that is rarely included in routine health checks may reveal hidden heart and stroke risk.
New findings from more than 20,000 people suggest that very high levels of lipoprotein(a), usually shortened to Lp(a), are linked to a greater chance of serious cardiovascular problems even after other risk factors and treatments are considered.
The findings were presented at the Society for Cardiovascular Angiography & Interventions 2026 Scientific Sessions and the Canadian Association of Interventional Cardiology summit in Montreal.
Because the results were presented at a scientific meeting, they should be considered preliminary until the full research has undergone complete peer review and publication.
Lp(a) is a particle that carries cholesterol through the bloodstream. It resembles LDL, commonly called bad cholesterol, but has an extra protein attached to it. This difference may make Lp(a) particularly important in the development of artery disease and blood clots.
Unlike many other cardiovascular risk factors, Lp(a) is largely controlled by genes. Diet, exercise and weight loss usually have much less influence on it than they do on ordinary LDL cholesterol. A person can therefore live a healthy lifestyle and have apparently acceptable cholesterol results while still carrying a high Lp(a) level.
High Lp(a) is also common. About one in five people is estimated to have an elevated level, yet most do not know it because it generally produces no symptoms. The only practical way to discover it is through a blood test.
Scientists have known for years that high Lp(a) is associated with cardiovascular disease. The new analysis was designed to provide more information about how different levels relate to future events, especially in people who already have heart disease.
Researchers used stored blood samples from 20,070 adults aged 40 or older who had participated in three large studies funded by the U.S. National Institutes of Health: ACCORD, PEACE and SPRINT. These trials originally investigated major cardiovascular and metabolic health questions. The stored samples allowed scientists to ask a new question years later.
The participants had an average age of about 65, and roughly two-thirds were men. Researchers measured Lp(a) using the same laboratory method and divided people into four groups according to their blood levels. They also separated participants according to whether they already had cardiovascular disease.
The main outcome was a group of serious cardiovascular events. These included heart attack, stroke, death from a heart-related cause and procedures needed to restore blood flow through narrowed or blocked heart arteries. Participants were followed for a median of about four years.
During that period, 1,461 people experienced one of these major events. That represented about 7.3 percent of the study population. The clearest increase in risk appeared among people with Lp(a) levels of at least 175 nanomoles per liter.
After researchers accounted for factors such as age, other illnesses, cholesterol levels and treatments, people in this very-high-Lp(a) group had about a 31 percent higher risk of a major cardiovascular event. Their risk of cardiovascular death was about 49 percent higher. Their risk of stroke was about 64 percent higher.
Interestingly, very high Lp(a) was not associated with a statistically significant increase in heart attacks in this analysis. This shows that Lp(a) may not influence every cardiovascular outcome in exactly the same way. Researchers will need more work to understand why the association appeared particularly strong for stroke and cardiovascular death.
The relationship was also more convincing among people who already had heart disease. In that group, very high Lp(a) was associated with about a 30 percent higher risk of major cardiovascular events. Among people without established heart disease, the estimated increase was smaller and the statistical evidence was not strong enough to rule out chance.
This distinction could matter in clinical practice. Someone who already has coronary disease has a higher starting risk, so an inherited factor such as Lp(a) may add another layer of danger. Identifying that extra risk could encourage doctors and patients to be especially careful about factors that can be changed.
At present, people cannot easily lower genetically high Lp(a) through lifestyle alone. However, they can address other risks. Doctors may recommend tighter control of LDL cholesterol, blood pressure, diabetes, smoking and other cardiovascular factors depending on the person’s medical history.
This does not mean everyone with high Lp(a) will develop heart disease or have a stroke. Risk factors change probability rather than determine an individual’s future. A person’s overall cardiovascular risk depends on the combination of genetics, age, blood pressure, cholesterol, smoking, diabetes and many other influences.
The study also does not prove that lowering Lp(a) itself will prevent strokes or deaths. It measured associations between naturally occurring Lp(a) levels and later outcomes. Clinical trials of drugs designed specifically to lower Lp(a) are needed to show whether reducing the particle actually improves health.
Several targeted Lp(a)-lowering treatments are being developed, making the question increasingly important. If those medicines prove that lowering Lp(a) reduces cardiovascular events, a one-time or occasional blood test could become more useful for identifying people who might benefit from treatment.
The large number of participants is a major strength of the analysis. Using samples from three established NIH trials also provided detailed information about participants’ health and treatment. A standardized laboratory test made comparisons between people more reliable.
However, the analysis has limitations. It combines participants from trials that were originally designed for other purposes, and the follow-up was around four years rather than decades. The findings were also presented as late-breaking research at a conference, so the complete published analysis will be important for judging the results in detail.
Overall, the findings strengthen the case that very high Lp(a) can identify cardiovascular risk that ordinary cholesterol testing may miss. The signal was particularly notable for stroke and cardiovascular death and appeared stronger in people who already had heart disease.
For now, knowing about high Lp(a) may be most useful as a reason to manage the heart risks that can already be treated while researchers wait for evidence on new Lp(a)-specific therapies.
If you care about stroke, please read studies about how to eat to prevent stroke, and diets high in flavonoids could help reduce stroke risk.
For more health information, please see recent studies about how Mediterranean diet could protect your brain health, and wild blueberries can benefit your heart and brain.
Source: Society for Cardiovascular Angiography & Interventions.
